These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32806997)

  • 21. Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
    Chen X; He G; Lin S; Wang S; Sun F; Chen J; Zhang W
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33361124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New drugs and perspectives for new anti-tuberculosis regimens.
    Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
    Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.
    Ernest JP; Sarathy J; Wang N; Kaya F; Zimmerman MD; Strydom N; Wang H; Xie M; Gengenbacher M; Via LE; Barry CE; Carter CL; Savic RM; Dartois V
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0050621. PubMed ID: 34252307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
    Zumla AI; Gillespie SH; Hoelscher M; Philips PP; Cole ST; Abubakar I; McHugh TD; Schito M; Maeurer M; Nunn AJ
    Lancet Infect Dis; 2014 Apr; 14(4):327-40. PubMed ID: 24670627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis.
    Rollo RF; Mori G; Hill TA; Hillemann D; Niemann S; Homolka S; Fairlie DP; Blumenthal A
    Microbiol Spectr; 2023 Aug; 11(4):e0046523. PubMed ID: 37289062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring in the treatment of tuberculosis: an update.
    Alsultan A; Peloquin CA
    Drugs; 2014 Jun; 74(8):839-54. PubMed ID: 24846578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of new drug-regimens against multidrug-resistant tuberculosis.
    Vasava MS; Nair SG; Rathwa SK; Patel DB; Patel HD
    Indian J Tuberc; 2019 Jan; 66(1):12-19. PubMed ID: 30797268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design.
    Lyons MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):211-219. PubMed ID: 33440076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches.
    Hanna D; Romero K; Schito M
    Int J Infect Dis; 2017 Mar; 56():208-211. PubMed ID: 27789338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis.
    Zhong X; Lin A; Luo J; Li Y; Chen J; Ning C; Cao F
    Postgrad Med J; 2024 May; 100(1184):366-372. PubMed ID: 38200633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Bolhuis MS; Akkerman OW; Sturkenboom MGG; Ghimire S; Srivastava S; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S327-S335. PubMed ID: 30496467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
    Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
    mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in the clinical assessment of novel tuberculosis drugs.
    Dooley KE; Phillips PP; Nahid P; Hoelscher M
    Adv Drug Deliv Rev; 2016 Jul; 102():116-22. PubMed ID: 26827911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
    Martins M
    Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.
    Dartois V; Barry CE
    Curr Clin Pharmacol; 2010 May; 5(2):96-114. PubMed ID: 20156156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.